Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

(2017) A. Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer

(2017) N. Wallis et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody

(2008) Luis H Camacho   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Next Generation of Immunotherapy for Melanoma

(2008) John M. Kirkwood et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

(2008) Begoña Comin-Anduix et al.   Journal of Translational Medicine